Selling a Pain Management Practice in 2026: Multiples, Named Buyers, and the Operator Playbook
Quick Answer
A US interventional pain management practice in 2026 typically sells for roughly 4x to 11x EBITDA. By profile: single-MD pain practice at $500k-1.5M EBITDA goes 4x-6x; multi-MD single-site or 2-3 locations ($1.5-4M EBITDA) goes 5x-7x; small regional pain group with ASC ownership (3-10 providers, $3-8M EBITDA) goes 6x-9x; mid-size pain platform ($5-15M EBITDA, multi-site, ASC ownership, diversified service mix incl. SCS/intrathecal/RFA/injections) goes 7x-10x; premium scale platform ($15M+ EBITDA, multi-state, ASC ownership, named in-network commercial contracts) reaches 9x-11x+. Active buyers include US Anesthesia Partners (USAP, PE-backed by Welsh Carson + Berkshire + GIC, the largest US anesthesia + pain platform), North American Partners in Anesthesia (NAPA, American Securities), National Spine & Pain Centers (PE-backed, multi-state), Resurgens Orthopaedics + Pinnacle Spine & Pain (PE-backed), Optum Health pain segment, Specialty Care (PE), Anesthesia Services Affiliates (PE-backed), plus PE sponsors (Welsh Carson, American Securities, Berkshire Partners, GIC, Audax Group, BlueMountain Capital, Webster Equity, Aterian Investment Partners). The biggest multiple drivers are ASC ownership (Stark-compliant), procedural mix (SCS – spinal cord stimulator implants, intrathecal pumps, RFA – radiofrequency ablation, transforaminal epidurals, facet blocks command premium to injection-only practices), commercial payer mix, opioid prescribing compliance (PDMP, naloxone co-prescribing, MAT integration), and modern EMR (Modernizing Medicine EMA-Pain, Practice Fusion-Pain, Nextech). Buyer-paid M&A advisory (CT Strategic Partners) costs the seller nothing.
If you own a pain management practice in 2026, the M&A market is consolidated and PE-deep. US Anesthesia Partners (Welsh Carson + Berkshire + GIC) is the dominant anesthesia + pain platform. NAPA (American Securities) is the second major platform. National Spine & Pain Centers operates a multi-state pain-specific platform. Mid-size PE-backed pain platforms continue rolling up regional groups.
What the asset is worth depends on three things: (1) ASC ownership and Stark-compliant structure (ASC ownership is the major multiple-builder in pain), (2) procedural mix (SCS implants, intrathecal pumps, RFA, transforaminal epidurals premium to injection-only), and (3) opioid prescribing compliance (PDMP integration, naloxone co-prescribing, MAT capability where applicable). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.
What this guide covers
- Pain management multiples 2026: 4x-6x for single-MD, 5x-7x for multi-MD single-site, 6x-9x for small regional with ASC, 7x-10x for mid-size platforms, 9x-11x+ for premium scale multi-state with ASC + in-network commercial.
- Active buyers: US Anesthesia Partners (USAP, Welsh Carson + Berkshire + GIC), NAPA (American Securities), National Spine & Pain Centers, Resurgens / Pinnacle Spine & Pain, Optum Health pain segment, Specialty Care, Anesthesia Services Affiliates.
- PE sponsor activity: Welsh, Carson, Anderson & Stowe + Berkshire Partners + GIC (USAP), American Securities (NAPA), Audax Group, BlueMountain Capital, Webster Equity, Aterian Investment Partners.
- Multiple drivers: ASC ownership and Stark-compliant structure (the major multiple-builder), procedural mix (SCS, intrathecal pumps, RFA, transforaminal epidurals), commercial payer mix, opioid prescribing compliance (PDMP, naloxone, MAT integration), modern EMR.
- Things that compress the multiple: injection-only practice without procedural diversification, opioid prescribing compliance issues, no ASC ownership, owner-MD dependence, Medicare-heavy payer mix, single-MD-only practices.
- Sellers pay nothing on CT Strategic Partners’ buyer-paid advisory.
Named pain management / anesthesia M&A transactions (2022-2025)
| Target | Buyer | Year | What it tells us |
|---|---|---|---|
| Multiple USAP regional tuck-ins | US Anesthesia Partners (Welsh Carson + Berkshire + GIC) | 2022-2025 | Dominant anesthesia + pain platform continues consolidation across the US. |
| NAPA continued M&A | American Securities | 2022-2025 | Second-largest anesthesia platform continues regional tuck-in M&A. |
| National Spine & Pain Centers growth | PE-backed | 2022-2025 | PE-backed pain-specific platform continues multi-state expansion. |
| Pinnacle Spine & Pain expansion | PE-backed | 2022-2025 | PE-backed pain platform continues regional rollups. |
| FTC vs. USAP litigation | Federal Trade Commission | 2023 | FTC sued USAP alleging anti-competitive M&A roll-up patterns. Case ongoing; tested PE roll-up regulatory limits. |
The named buyer landscape
National anesthesia + pain platforms
- US Anesthesia Partners (USAP) — PE-backed by Welsh, Carson, Anderson & Stowe + Berkshire Partners + GIC, ~$2.5B+ revenue. The dominant US anesthesia + pain platform.
- NAPA (North American Partners in Anesthesia) — American Securities, ~$1.8B+ revenue. Second-largest.
Pain-specific PE-backed platforms
- National Spine & Pain Centers — PE-backed, multi-state pain platform.
- Pinnacle Spine & Pain — PE-backed.
- Resurgens Orthopaedics — Atlanta-anchored ortho + pain.
- Specialty Care — PE-backed ambulatory specialty platform.
- Anesthesia Services Affiliates — PE-backed.
Strategic buyers
- Optum Health pain segment — UnitedHealth Group, selective.
- Hospital systems acquire pain practices for outpatient access in their footprint.
PE sponsors active in this space
- Welsh, Carson, Anderson & Stowe + Berkshire Partners + GIC (USAP), American Securities (NAPA), Audax Group, BlueMountain Capital, Webster Equity Partners, Aterian Investment Partners.
What each buyer will pay for vs. what they reject
- Will pay premium for: ASC ownership with Stark-compliant structure, diversified procedural mix (SCS spinal cord stimulator implants, intrathecal pumps, RFA radiofrequency ablation, transforaminal epidurals, facet blocks, kyphoplasty), commercial payer mix (50%+ commercial), clean opioid prescribing compliance with PDMP integration and naloxone co-prescribing, modern EMR (Modernizing Medicine EMA-Pain, Nextech), multi-state professional licensure, MAT (medication-assisted treatment) integration where applicable.
- Will compress or reject: injection-only practice without procedural diversification, opioid prescribing compliance issues (DEA investigations, opioid-overdose patient deaths in care), no ASC ownership, owner-MD dependence, Medicare-heavy payer mix above 60%, single-MD-only practices, weak commercial in-network status, Stark/anti-kickback exposure on ASC arrangements.
The operator-level KPI playbook buyers will diligence
Procedural mix
- SCS (spinal cord stimulator) implants: Volume per year, payer mix.
- Intrathecal pump implants and refills.
- RFA (radiofrequency ablation): Cervical, lumbar, thoracic facet RFA volume.
- Transforaminal epidural injections.
- Facet joint injections / medial branch blocks.
- Kyphoplasty / vertebroplasty volume.
- Sympathetic blocks, stellate ganglion blocks.
- Average revenue per procedure type.
ASC ownership and structure
- ASC ownership: Wholly-owned vs. JV with Surgery Partners / USPI / hospital.
- Stark-compliant structure: In-office ancillary services exception or group practice exception.
- ASC accreditation: AAAHC, AAAASF, Joint Commission ambulatory.
- ASC case volume and revenue.
Opioid prescribing compliance
- PDMP (Prescription Drug Monitoring Program) integration: Document state-PDMP queries on every prescription.
- Naloxone co-prescribing rate: Best practice for high-MED patients.
- Pain management agreements: Documented patient agreements.
- UDS (urine drug screening) frequency and compliance.
- MED (morphine equivalent daily) dose tracking.
- MAT integration: Suboxone or methadone for OUD patients.
- DEA inspection history.
Payer mix
- Commercial percentage: 50%+ is the platform benchmark.
- Workers’-comp percentage.
- Medicare percentage: 25-40% typical.
- Auto/PIP percentage.
- Single-payer concentration: No single payer above 25%.
Provider productivity
- Encounters per day per MD.
- Procedures per week per interventional MD.
- PA/NP scope and supervision.
- Provider compensation model.
EMR and operating system
- EMR: Modernizing Medicine EMA-Pain (operator standard), Nextech, EHR with pain-specific templates.
- PDMP integration.
- UDS workflow.
Dangers and traps in pain management M&A
1. Opioid prescribing compliance and DEA exposure
DEA investigations, state Medical Board complaints, opioid-overdose patient deaths in care, or controlled-substance prescribing patterns outside CDC guidelines are binary deal-killers. Document compliance posture cleanly.
2. Stark and anti-kickback exposure on ASC arrangements
Physician-owned ASC arrangements must be Stark-compliant.
3. Injection-only practice without procedural diversification
Premium multiples require diversified procedural mix (SCS, intrathecal pumps, RFA, kyphoplasty). Injection-only practices compress.
4. Owner-MD dependence
Build the interventional MD bench.
5. FTC scrutiny on PE roll-ups
FTC sued USAP in 2023 alleging anti-competitive roll-up patterns. The PE roll-up regulatory environment for anesthesia/pain is uncertain through 2026. Document local market dynamics.
6. Medicare-heavy payer mix
Above 60% Medicare compresses the multiple.
7. MAT integration or referral pathways
If chronic pain patients transition to OUD, MAT integration or documented MAT referral pathways are best practice. Without them, opioid prescribing risk profile is higher.
8. Equity-rollover expectations
PE-MSO pain deals include 20-40% equity rollover.
Our POV on pain management M&A in 2026
Pain management M&A is highly active with the dominant anesthesia + pain platforms (USAP, NAPA) and pain-specific PE-backed platforms (National Spine & Pain, Pinnacle Spine & Pain) actively rolling up. The FTC vs. USAP litigation in 2023 has introduced regulatory uncertainty on PE roll-ups in this sector. Premium multiples require ASC ownership, diversified procedural mix, and clean opioid prescribing compliance.
Preparing your pain management practice for sale: 12-18 months out
- Get multi-year audited or reviewed financials.
- Audit opioid prescribing compliance. PDMP integration, naloxone co-prescribing, UDS frequency, MED tracking.
- Structure Stark-compliant ASC arrangements.
- Diversify procedural mix. Build SCS, intrathecal, RFA, kyphoplasty capabilities.
- Confirm commercial in-network status.
- Modernize the EMR. Modernizing Medicine EMA-Pain or Nextech.
- Develop the MD/PA bench.
- Integrate MAT or MAT referral pathways.
- Run a competitive process. USAP, NAPA, National Spine & Pain Centers, Pinnacle Spine & Pain, Specialty Care, plus PE sponsors directly.
Free, No Email Required
Get a personalized valuation in 90 seconds
Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.
Open the Valuation Tool →The five pillars of how CT Acquisitions works
Buyer pays our fee. Founders never write a check.
No engagement letter. No upfront cost. No exclusivity contract.
Search funders, family offices, lower-middle-market PE, strategics.
Confidential introductions to the right buyers. No bidding war.
Not 9-12 months. Not 18 months. Months, not years.
No Pitch · No Pressure
Ready to start a confidential conversation?
Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next 60-120 days could look like. No engagement letter. No retainer. Walk at any time.
Start a Confidential Conversation →Frequently asked questions
What is the typical multiple for a pain management practice in 2026?
Single-MD pain practices ($500k-1.5M EBITDA) typically sell at 4x-6x EBITDA. Multi-MD single-site or 2-3 location practices ($1.5-4M EBITDA) go 5x-7x. Small regional groups with ASC ownership ($3-8M EBITDA) go 6x-9x. Mid-size pain platforms ($5-15M EBITDA, multi-site + ASC, diversified procedural mix) go 7x-10x. Premium scale platforms ($15M+ EBITDA, multi-state, ASC ownership, named in-network commercial contracts) reach 9x-11x+.
Who are the active buyers of pain management practices right now?
National anesthesia + pain platforms: US Anesthesia Partners (USAP, PE-backed by Welsh, Carson, Anderson & Stowe + Berkshire Partners + GIC, ~$2.5B+ revenue), NAPA / North American Partners in Anesthesia (American Securities, ~$1.8B+). Pain-specific PE-backed platforms: National Spine & Pain Centers, Pinnacle Spine & Pain, Resurgens Orthopaedics, Specialty Care, Anesthesia Services Affiliates. Strategic: Optum Health pain segment. PE sponsors: Welsh Carson + Berkshire + GIC, American Securities, Audax Group, BlueMountain Capital, Webster Equity Partners, Aterian Investment Partners.
What hurts a pain management practice’s valuation most?
Opioid prescribing compliance issues (DEA investigations, state Medical Board complaints, opioid-overdose patient deaths), Stark or anti-kickback exposure on ASC arrangements, injection-only practice without procedural diversification, no ASC ownership, owner-MD dependence, Medicare-heavy payer mix above 60%, single-MD-only practices, and undocumented MAT integration for chronic pain patients.
Why is ASC ownership so important in pain management?
ASC (ambulatory surgery center) ownership provides material additional EBITDA from facility fees on interventional procedures (SCS, intrathecal pumps, RFA, kyphoplasty), and creates a buyer-attractive surgical platform. Stark-compliant ASC structures are essential. ASCs typically add 2-3 turns of EBITDA multiple over no-ASC pain practices when properly structured.
What is the FTC vs. USAP litigation?
In 2023 the Federal Trade Commission sued US Anesthesia Partners alleging anti-competitive roll-up M&A patterns in Texas. The case has been ongoing through 2025 and is testing the regulatory limits of PE roll-ups in the anesthesia/pain sector. The outcome could affect future PE-platform M&A in pain. Premium multi-state platforms may face heightened regulatory scrutiny.
Do I have to pay a broker fee?
No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.
How long does it take to sell a pain management practice?
Once you go to market with a buyer-paid advisor, a typical process runs 6-9 months from initial outreach to closing, with regulatory and opioid-compliance diligence extending the timeline. Add 12-18 months of preparation work before going to market.
When should I start preparing if I plan to sell in 2027 or 2028?
12-18 months before going to market is the right window. Highest-leverage pre-sale work: audit and document opioid prescribing compliance, structure Stark-compliant ASC arrangements, diversify procedural mix (SCS, intrathecal, RFA, kyphoplasty), confirm commercial in-network status, modernize EMR, and develop the MD/PA bench.
Related research
- How to sell an addiction treatment center
- How to sell an ophthalmology practice
- How to sell a dermatology practice
- How to sell a physical therapy practice
- How to sell an urgent care center
- How to sell an imaging center
- How to sell a behavioral health practice
- Healthcare business valuation
- Which industries is PE buying most in 2026
- Business broker alternative
About the Author
Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch